Effects of empagliflozin in women and men with acute myocardial infarction: An analysis from the EMMY trial

the EMMY study group

doi:10.1016/j.hjc.2023.05.007

Effects of empagliflozin in women and men with acute myocardial infarction: An analysis from the EMMY trial

the EMMY study group

Research output: Contribution to journal › Article › peer-review

10 Citations (Scopus)

Abstract

Objective: Women have a higher comorbidity burden and a lower survival rate after acute myocardial infarction (AMI) than men. This analysis aimed to investigate the impact of sex on the effect of treatment with the sodium glucose cotransporter 2 inhibitor (SGLT2i) empagliflozin immediately after an AMI. Methods: Participants were randomized to either empagliflozin or placebo and followed for 26 weeks after initiating the treatment no later than 72 hours after a percutaneous coronary intervention following an AMI. We analyzed the impact of sex on the beneficial effects of empagliflozin observed for heart failure biomarkers as well as structural and functional cardiac parameters. Results: Women had higher NT-proBNP levels at baseline (median 2117pg/mL, IQR 1383-3267 pg/mL versus 1137 pg/mL, IQR 695-2050 pg/mL; p < 0.001) and were older than men (median 61y, IQR 56-65y versus 56y, IQR 51-64y, p = 0.005). The beneficial effects of empagliflozin on NT-proBNP levels (P_interaction = 0.984), left ventricular ejection fraction (P_interaction = 0.812), left ventricular end systolic volume (P_interaction = 0.183), or left ventricular end diastolic volume (P_interaction = 0.676) were independent of sex. Conclusions: Empagliflozin exhibited similar benefits in women and men when administered immediately after an AMI.

Original language	English
Pages (from-to)	3-8
Number of pages	6
Journal	Hellenic Journal of Cardiology
Volume	75
DOIs	https://doi.org/10.1016/j.hjc.2023.05.007
Publication status	Published - Jan 1 2024
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Acute Myocardial Infarction
Cardiovascular Disease
Empagliflozin
SGLT2i
Sex Differences

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.hjc.2023.05.007

Cite this

@article{397f62e099554589b6fa9639646624e1,

title = "Effects of empagliflozin in women and men with acute myocardial infarction: An analysis from the EMMY trial",

abstract = "Objective: Women have a higher comorbidity burden and a lower survival rate after acute myocardial infarction (AMI) than men. This analysis aimed to investigate the impact of sex on the effect of treatment with the sodium glucose cotransporter 2 inhibitor (SGLT2i) empagliflozin immediately after an AMI. Methods: Participants were randomized to either empagliflozin or placebo and followed for 26 weeks after initiating the treatment no later than 72 hours after a percutaneous coronary intervention following an AMI. We analyzed the impact of sex on the beneficial effects of empagliflozin observed for heart failure biomarkers as well as structural and functional cardiac parameters. Results: Women had higher NT-proBNP levels at baseline (median 2117pg/mL, IQR 1383-3267 pg/mL versus 1137 pg/mL, IQR 695-2050 pg/mL; p < 0.001) and were older than men (median 61y, IQR 56-65y versus 56y, IQR 51-64y, p = 0.005). The beneficial effects of empagliflozin on NT-proBNP levels (Pinteraction = 0.984), left ventricular ejection fraction (Pinteraction = 0.812), left ventricular end systolic volume (Pinteraction = 0.183), or left ventricular end diastolic volume (Pinteraction = 0.676) were independent of sex. Conclusions: Empagliflozin exhibited similar benefits in women and men when administered immediately after an AMI.",

keywords = "Acute Myocardial Infarction, Cardiovascular Disease, Empagliflozin, SGLT2i, Sex Differences",

author = "\{the EMMY study group\} and Caren Sourij and Faisal Aziz and Tripolt, \{Norbert J.\} and Jolanta Siller-Matula and Pferschy, \{Peter N.\} and Ewald Kolesnik and Markus Wallner and Ceren Eyileten and Marek Postula and Abderrahim Oulhaj and Harald Sourij and \{von Lewinski\}, Dirk",

note = "Publisher Copyright: {\textcopyright} 2023 Hellenic Society of Cardiology",

year = "2024",

month = jan,

day = "1",

doi = "10.1016/j.hjc.2023.05.007",

language = "English",

volume = "75",

pages = "3--8",

journal = "Hellenic Journal of Cardiology",

issn = "1109-9666",

publisher = "Hellenic Cardiological Society",

}

TY - JOUR

T1 - Effects of empagliflozin in women and men with acute myocardial infarction

T2 - An analysis from the EMMY trial

AU - the EMMY study group

AU - Sourij, Caren

AU - Aziz, Faisal

AU - Tripolt, Norbert J.

AU - Siller-Matula, Jolanta

AU - Pferschy, Peter N.

AU - Kolesnik, Ewald

AU - Wallner, Markus

AU - Eyileten, Ceren

AU - Postula, Marek

AU - Oulhaj, Abderrahim

AU - Sourij, Harald

AU - von Lewinski, Dirk

PY - 2024/1/1

Y1 - 2024/1/1

N2 - Objective: Women have a higher comorbidity burden and a lower survival rate after acute myocardial infarction (AMI) than men. This analysis aimed to investigate the impact of sex on the effect of treatment with the sodium glucose cotransporter 2 inhibitor (SGLT2i) empagliflozin immediately after an AMI. Methods: Participants were randomized to either empagliflozin or placebo and followed for 26 weeks after initiating the treatment no later than 72 hours after a percutaneous coronary intervention following an AMI. We analyzed the impact of sex on the beneficial effects of empagliflozin observed for heart failure biomarkers as well as structural and functional cardiac parameters. Results: Women had higher NT-proBNP levels at baseline (median 2117pg/mL, IQR 1383-3267 pg/mL versus 1137 pg/mL, IQR 695-2050 pg/mL; p < 0.001) and were older than men (median 61y, IQR 56-65y versus 56y, IQR 51-64y, p = 0.005). The beneficial effects of empagliflozin on NT-proBNP levels (Pinteraction = 0.984), left ventricular ejection fraction (Pinteraction = 0.812), left ventricular end systolic volume (Pinteraction = 0.183), or left ventricular end diastolic volume (Pinteraction = 0.676) were independent of sex. Conclusions: Empagliflozin exhibited similar benefits in women and men when administered immediately after an AMI.

AB - Objective: Women have a higher comorbidity burden and a lower survival rate after acute myocardial infarction (AMI) than men. This analysis aimed to investigate the impact of sex on the effect of treatment with the sodium glucose cotransporter 2 inhibitor (SGLT2i) empagliflozin immediately after an AMI. Methods: Participants were randomized to either empagliflozin or placebo and followed for 26 weeks after initiating the treatment no later than 72 hours after a percutaneous coronary intervention following an AMI. We analyzed the impact of sex on the beneficial effects of empagliflozin observed for heart failure biomarkers as well as structural and functional cardiac parameters. Results: Women had higher NT-proBNP levels at baseline (median 2117pg/mL, IQR 1383-3267 pg/mL versus 1137 pg/mL, IQR 695-2050 pg/mL; p < 0.001) and were older than men (median 61y, IQR 56-65y versus 56y, IQR 51-64y, p = 0.005). The beneficial effects of empagliflozin on NT-proBNP levels (Pinteraction = 0.984), left ventricular ejection fraction (Pinteraction = 0.812), left ventricular end systolic volume (Pinteraction = 0.183), or left ventricular end diastolic volume (Pinteraction = 0.676) were independent of sex. Conclusions: Empagliflozin exhibited similar benefits in women and men when administered immediately after an AMI.

KW - Acute Myocardial Infarction

KW - Cardiovascular Disease

KW - Empagliflozin

KW - SGLT2i

KW - Sex Differences

UR - https://www.scopus.com/pages/publications/85176783628

UR - https://www.scopus.com/pages/publications/85176783628#tab=citedBy

U2 - 10.1016/j.hjc.2023.05.007

DO - 10.1016/j.hjc.2023.05.007

M3 - Article

C2 - 37236318

AN - SCOPUS:85176783628

SN - 1109-9666

VL - 75

SP - 3

EP - 8

JO - Hellenic Journal of Cardiology

JF - Hellenic Journal of Cardiology

ER -

Effects of empagliflozin in women and men with acute myocardial infarction: An analysis from the EMMY trial

Abstract

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this